Imerio Capone
Overview
Explore the profile of Imerio Capone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Romagnoli G, DAlessandris Q, Capone I, Tavilla A, Canini I, Lapenta C, et al.
Immunology
. 2023 Oct;
171(2):198-211.
PMID: 37884280
Glioblastoma, isocitrate dehydrogenase-wildtype (GB), is the most common and aggressive primary brain malignancy with poor outcome. Immune checkpoint inhibitors (ICIs) have been tested in GB and, despite disappointing results, the...
2.
Fragale A, Stellacci E, Romagnoli G, Licursi V, Parlato S, Canini I, et al.
Int J Cancer
. 2023 Jun;
153(5):1080-1095.
PMID: 37293858
BRAF mutations are the most common oncogenic alterations in melanoma cells, supporting proliferation, invasion, metastasis and immune evasion. In patients, these aberrantly activated cellular pathways are inhibited by BRAFi whose...
3.
Gabriele L, Fragale A, Romagnoli G, Parlato S, Lapenta C, Santini S, et al.
Cytokine Growth Factor Rev
. 2020 Oct;
58:66-74.
PMID: 33071044
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, induces severe pneumonia mainly in elderly males. Epidemiological data clearly indicate sex-based...
4.
Urbani F, Ferraresi V, Capone I, Macchia I, Palermo B, Nuzzo C, et al.
Front Oncol
. 2020 Mar;
10:202.
PMID: 32211314
Clinical studies based on novel rationales and mechanisms of action of chemotherapy agents and cytokines can contribute to the development of new concepts and strategies of antitumor combination therapies. In...
5.
Arico E, Castiello L, Capone I, Gabriele L, Belardelli F
Cancers (Basel)
. 2019 Dec;
11(12).
PMID: 31817234
The first report on the antitumor effects of interferon α/β (IFN-I) in mice was published 50 years ago. IFN-α were the first immunotherapeutic drugs approved by the FDA for clinical...
6.
Cox M, Castiello L, Mattei M, Santodonato L, DAgostino G, Muraro E, et al.
Clin Cancer Res
. 2019 Jun;
25(17):5231-5241.
PMID: 31171545
Purpose: This study was aimed at evaluating the feasibility, safety, immunologic and clinical responses in patients with follicular lymphoma treated with monocyte-derived dendritic cells generated in the presence of IFNα...
7.
Capone I, Marchetti P, Ascierto P, Malorni W, Gabriele L
Front Immunol
. 2018 Apr;
9:552.
PMID: 29619026
Nowadays, several types of tumors can benefit from the new frontier of immunotherapy, due to the recent increasing knowledge of the role of the immune system in cancer control. Among...
8.
Fragale A, Romagnoli G, Licursi V, Buoncervello M, Del Vecchio G, Giuliani C, et al.
Cancer Immunol Res
. 2017 Jun;
5(7):604-616.
PMID: 28615266
Colorectal cancer results from the progressive accumulation of genetic and epigenetic alterations. IFN signaling defects play an important role in the carcinogenesis process, in which the inability of IFN transcription...
9.
Buoncervello M, Romagnoli G, Buccarelli M, Fragale A, Toschi E, Parlato S, et al.
Oncotarget
. 2016 Mar;
7(18):26361-73.
PMID: 27028869
Epigenetic alterations, including dysregulated DNA methylation and histone modifications, govern the progression of colorectal cancer (CRC). Cancer cells exploit epigenetic regulation to control cellular pathways, including apoptotic and metastatic signals....
10.
Rozera C, Antonini Cappellini G, DAgostino G, Santodonato L, Castiello L, Urbani F, et al.
J Transl Med
. 2015 May;
13:139.
PMID: 25933939
Background: Advanced melanoma patients have an extremely poor long term prognosis and are in strong need of new therapies. The recently developed targeted therapies have resulted in a marked antitumor...